Cargando…
A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients
Autores principales: | Snook, Adam, Baybutt, Trevor, Mastrangelo, Michael, Lewis, Nancy, Goldstein, Scott, Kraft, Walter, Oppong, Yaa, Hyslop, Terry, Myers, Ronald, Alexeev, Vitali, Eisenlohr, Laurence, Sato, Takami, Waldman, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652457/ http://dx.doi.org/10.1186/2051-1426-3-S2-P450 |
Ejemplares similares
-
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
por: Snook, Adam E., et al.
Publicado: (2019) -
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
por: Magee, Michael S., et al.
Publicado: (2016) -
GUCY2C at the intersection of obesity and colorectal cancer
por: Waldman, Scott A, et al.
Publicado: (2013) -
Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
por: Flickinger Jr, John C, et al.
Publicado: (2020) -
GUCY2C maintains intestinal LGR5(+) stem cells by opposing ER stress
por: Kraft, Crystal L., et al.
Publicado: (2017)